|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
177,680,000 |
Market
Cap: |
10.91(B) |
Last
Volume: |
1,933,966 |
Avg
Vol: |
1,913,064 |
52
Week Range: |
$56.27 - $99.04 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 568 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
103,519 |
108,398 |
180,881 |
290,334 |
Total Sell Value |
$6,219,303 |
$6,570,910 |
$12,429,896 |
$18,676,003 |
Total People Sold |
10 |
10 |
11 |
11 |
Total Sell Transactions |
49 |
52 |
65 |
100 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-27 |
4 |
AS |
$56.89 |
$115,316 |
D/D |
(2,027) |
11,694 |
|
9% |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,954 |
75,612 |
|
- |
|
Herriott James |
General Counsel |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,648 |
8,881 |
|
- |
|
Conroy Kevin T |
President and CEO |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,181 |
1,295,887 |
|
- |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,701 |
10,764 |
|
- |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,954 |
13,633 |
|
- |
|
Cunningham Everett |
Chief Commercial Officer |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,678 |
46,948 |
|
- |
|
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,954 |
13,721 |
|
- |
|
Conroy Kevin T |
President and CEO |
|
2024-02-23 |
4 |
D |
$57.53 |
$3,541,547 |
D/D |
(61,560) |
1,282,706 |
|
- |
|
Conroy Kevin T |
President and CEO |
|
2024-02-23 |
4 |
OE |
$13.96 |
$1,435,605 |
D/D |
102,837 |
1,344,266 |
|
- |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-23 |
4 |
AS |
$59.72 |
$60,974 |
D/D |
(1,021) |
71,658 |
|
8% |
|
Cunningham Everett |
Chief Commercial Officer |
|
2024-02-22 |
4 |
AS |
$59.78 |
$80,703 |
D/D |
(1,350) |
39,270 |
|
4% |
|
Conroy Kevin T |
President and CEO |
|
2024-02-22 |
4 |
AS |
$59.78 |
$691,356 |
D/D |
(11,565) |
1,241,429 |
|
4% |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-22 |
4 |
AS |
$59.78 |
$80,763 |
D/D |
(1,351) |
5,063 |
|
4% |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-22 |
4 |
AS |
$59.78 |
$60,557 |
D/D |
(1,013) |
9,679 |
|
4% |
|
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-22 |
4 |
AS |
$59.78 |
$65,340 |
D/D |
(1,093) |
9,767 |
|
4% |
|
Coward D Scott |
Director |
|
2024-02-22 |
4 |
AS |
$59.78 |
$39,634 |
D/D |
(663) |
44,493 |
|
4% |
|
Herriott James |
General Counsel |
|
2024-02-22 |
4 |
AS |
$59.78 |
$17,396 |
D/D |
(291) |
7,233 |
|
4% |
|
Condella Sarah |
EVP, Human Resources |
|
2024-02-22 |
4 |
AS |
$59.78 |
$60,557 |
D/D |
(1,013) |
72,679 |
|
4% |
|
Cunningham Everett |
Chief Commercial Officer |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,711 |
40,620 |
|
- |
|
Conroy Kevin T |
President and CEO |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
23,238 |
1,252,994 |
|
- |
|
Elliott Jeffrey Thomas |
Chief Financial Officer |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,711 |
6,414 |
|
- |
|
Orville Jacob A |
General Manager, Screening |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,034 |
10,692 |
|
- |
|
Baranick Brian |
Gen. Mgr., Precision Oncology |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,034 |
10,860 |
|
- |
|
Coward D Scott |
Director |
|
2024-02-21 |
4 |
A |
$0.00 |
$0 |
D/D |
2,034 |
45,156 |
|
- |
|
777 Records found
|
|
Page 2 of 32 |
|
|